Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity.
NPJ Vaccines
November 2024
Institute of Virology, University Hospital Bonn, Bonn, 53127, Germany.
In the present study, Pušnik et al. investigated whether the XBB.1.
View Article and Find Full Text PDFIdentification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis.
J Hepatol
August 2024
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; Research Group RNA Therapeutics & Liver Regeneration, REBIRTH-Research Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany. Electronic address:
Background & Aims: Liver fibrosis and its end-stage form cirrhosis contribute to millions of deaths annually. The lack of robust antifibrotic molecules is in part attributed to the absence of any functional screens to identify molecular regulators using patient-derived primary human hepatic myofibroblasts, which are key drivers of fibrosis.
Methods: Here, to identify robust regulators of fibrosis, we performed functional microRNA screenings in primary human hepatic myofibroblasts followed by in vivo validation in three independent mouse models of fibrosis (toxin, cholestasis and MASH).
Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies.
Hum Gene Ther
September 2024
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
All current market-approved gene therapy medical products for gene therapy of monogenic diseases rely on adeno-associated virus (AAV) vectors. Advances in gene editing technologies and vector engineering have expanded the spectrum of target cells and, thus, diseases that can be addressed. Consequently, AAV vectors are now being explored to modify cells of the hematopoietic system, including hematopoietic stem and progenitor cells (HSPCs), to develop novel strategies to treat monogenic diseases, but also to generate cell- and vaccine-based immunotherapies.
View Article and Find Full Text PDFDiagnostic delay in inflammatory bowel diseases in a German population.
World J Gastroenterol
August 2024
Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Berlin 10117, Germany.
Article Synopsis
- Early diagnosis is crucial for preventing bowel damage in inflammatory bowel disease (IBD), but studies on delayed diagnosis factors, particularly in German patients, are limited.
- A study involving 430 IBD patients in Berlin aimed to identify the reasons for prolonged diagnostic times, examining both patient and physician-related delays through a questionnaire.
- Results indicated that Crohn's disease patients faced significantly longer diagnostic delays compared to those with ulcerative colitis, with specific symptoms influencing the duration of physician diagnostic time for both conditions.
A longitudinal study on SARS-CoV-2 seroconversion, reinfection and neutralisation spanning several variant waves and vaccination campaigns, Heinsberg, Germany, April 2020 to November 2022.
Euro Surveill
June 2024
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany.
BackgroundSince its emergence in December 2019, over 700 million people worldwide have been infected with SARS-CoV-2 up to May 2024. While early rollout of mRNA vaccines against COVID-19 has saved many lives, there was increasing immune escape of new virus variants. Longitudinal monitoring of population-wide SARS-CoV-2 antibody responses from regular sample collection irrespective of symptoms provides representative data on infection and seroconversion/seroreversion rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!